Trends in survival and excess risk of death after diagnosis of cancer in 1980-1996 in New South Wales, Australia

- Yu, Xue Q., O'Connell, Dianne L., Gibberd, Robert W., Coates, Alan S., Armstrong, Bruce K.

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

- Rasmussen, Birgitte B., Regan, Meredith M., Braye, Stephen, Altermatt, Hans J., Gelber, Richard D., Castiglione-Gertsch, Monica, Goldhirsch, Aron, Gusterson, Barry A., Thürlimann, Beat, Coates, Alan S., Viale, Giuseppe, Lykkesfeldt, Anne E., Dell'Orto, Patrizia, Del Curto, Barbara, Henriksen, Katrine L., Mastropasqua, Mauro G., Price, Karen N., Méry, Eliane E., Lacroix-Triki, Magali

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors - International Breast Cancer Study Group

- Viale, Giuseppe, Regan, Meredith M., Braye, Stephen, Grigolato, Piergiovanni, Rusca, Tiziana, Gelber, Richard D., Castiglione-Gertsch, Monica, Price, Karen N., Goldhirsch, Aron, Gusterson, Barry A., Coates, Alan S., Maiorano, Eugenio, Mastropasqua, Mauro G., Golouh, Rastko, Perin, Tiziana, Brown, Robert W., Kovacs, Aniko, Pillay, Komala, Ohlschlegel, Christian

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial

- Crivellari, Diana, Sun, Zhuoxin, Gelber, Richard D., Colleoni, Marco, Lang, Istvan, Del Mastro, Lucia, Gladieff, Laurence, Rabaglio, Manuela, Smith, Ian E., Chirgwin, Jacquie H., Goldhirsch, Aron, Coates, Alan S., Price, Karen N., Thurlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert J., Castiglione-Gertsch, Monica

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93

- Pagani, Olivia, Gelber, Shari, Thürlimann, Beat, Fey, Martin F., Murray, Elizabeth, Forbes, John F., Coates, Alan S., Goldhirsch, Aron, Simoncini, Edda, Castiglione-Gertsch, Monica, Price, Karen N., Gelber, Richard D., Holmberg, Stig B., Crivellari, Diana, Collins, John, Lindtner, Jurij

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93

- Thürlimann, Beat, Price, Karen N., Goldhirsch, Aron, Gelber, Richard D., Holmberg, Stig B., Crivellari, Diana, Colleoni, Marco, Collins, John, Forbes, John F., Castiglione-Gertsch, Monica, Coates, Alan S.

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study

- Colleoni, Marco, Giobbie-Hurder, Anita, Chirgwin, Jacquie, Pienkowski, Tadeusz, Wardley, Andrew, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron, Regan, Meredith M., Thürlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert, Láng, István, Smith, Ian

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up

- Regan, Meredith M., Neven, Patrick, Rabaglio, Manuela, Price, Karen N., Gelber, Richard D., Coates, Alan S., Thürlimann, Beat, Giobbie-Hurder, Anita, Goldhirsch, Aron, Ejlertsen, Bent, Mauriac, Louis, Forbes, John F., Smith, Ian, Láng, István, Wardley, Andrew

Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer

- Stockler, Martin R., Harvey, Vernon J., Gainford, M. Corona, Fong, Akiko, Paksec, Lisa, Sourjina, Tatiana, Zannino, Diana, Gebski, Val, Simes, R. John, Forbes, John F., Coates, Alan S., Francis, Prudence A., Byrne, Michael J., Ackland, Stephen P., Fitzharris, Bernie, Van Hazel , Guy, Wilcken, Nicholas R. C., Grimison, Peter S., Nowak, Anna K.

Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study

- Bliss, Judith M., Kilburn, Lucy S., van de Velde, Cornelius J. H., Lønning, Per. E., Morden, James, Reise, Justine, Cisar, Laura, Menschik, Thomas, Coombes, R. Charles, Coleman, Robert E., Forbes, John F., Coates, Alan S., Jones, Stephen E., Jassem, Jack, Delozier, Thierry, Andersen, Jørn, Paridaens, Robert

Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial

- Ewertz, Marianne, Gray, Kathryn P., Gelber, Richard D., Colleoni, Marco, Láng, István, Smith, Ian E., Coates, Alan S., Goldhirsch, Aron, Mouridsen, Henning T., Regan, Meredith M., Ejlertsen, Bent, Price, Karen N., Thürlimann, Beat, Bonnefoi, Hervé, Forbes, John F., Paridaens, Robert J., Rabaglio, Manuela

Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials

- Regan, Meredith M., Pagani, Olivia, Colleoni, Marco, Gelber, Richard D., Francis, Prudence A., International Breast Cancer Study Group (IBCSG),, SOFT Investigators,, TEXT Investigators,, Fleming, Gini F., Walley, Barbara A., Price, Karen N., Rabaglio, Manuela, Maibach, Rudolf, Ruepp, Barbara, Coates, Alan S., Goldhirsch, Aron

Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone

- Lee, Chee Khoon, Gebski, Val J., Coates, Alan S., Veillard, Anne-Sophie, Harvey, Vernon, Tattersall, Martin H. N., Byrne, Michael J., Brigham, Brian, Forbes, John, Simes, R. John

Adjuvant ovarian suppression in premenopausal breast cancer

- Francis, Prudence A., Regan, Meredith M., Martino, Silvana, Davidson, Nancy E., Geyer, Charles E., Walley, Barbara A., Coleman, Robert, Kerbrat, Pierre, Buchholz, Stefan, Ingle, James N., Winer, Eric P., Rabaglio-Poretti, Manuela, Fleming, Gini F., Maibach, Rudolf, Ruepp, Barbara, Giobbie-Hurder, Anita, Price, Karen N., Colleoni, Marco, Viale, Giuseppe, Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Lang, István Láng, Ciruelos, Eva, Bellet, Meritxell, Bonnefoi, Hervé R., Climent, Miguel A., Da Prada, Gian Antonio, Burstein, Harold J.

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

- Bernhard, Jürg, Luo, Weixiu, Pavesi, Lorenzo, Parmar, Vani, Regan, Meredith M., Pagani, Olivia, Fleming, Gini F., Francis, Prudence A., Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Ribi, Karin, Walley, Barbara A., Colleoni, Marco, Burstein, Harold J., Tondini, Carlo, Pinotti, Graziella, Spazzapan, Simon, Ruhstaller, Thomas, Puglisi, Fabio

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

- Regan, Meredith M., Pagani, Olivia, Villani, Laura, Pizzolitto, Stefano, Öhlschlegel, Christian, Sessa, Fausto, Peg Cámara, Vicente, Rodríguez Peralto, José Luis, MacGrogan, Gaëtan, Colleoni, Marco, Goldhirsch, Aron, Price, Karen N., Francis, Prudence A., Coates, Alan S., Gelber, Richard D., Viale, Giuseppe, Fleming, Gini F., Walley, Barbara A., Kammler, Roswitha, Dell'Orto, Patrizia, Russo, Leila, Szőke, János, Doimi, Franco

Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT Trials

- Regan, Meredith M., Francis, Prudence A., Pinotti, Graziella, Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Pagani, Olivia, Fleming, Gini F., Walley, Barbara A., Viale, Giuseppe, Colleoni, Marco, Láng, István, Gómez, Henry L., Tondini, Carlo

Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial

- Ribi, Karin, Luo, Weixiu, Parmar, Vani, Tondini, Carlo, Kerbrat, Pierre, Perelló, Antonia, Neven, Patrick, Torres, Roberto, Lombardi, Davide, Puglisi, Fabio, Karlsson, Per, Ruhstaller, Thomas, Bernhard, Jürg, Colleoni, Marco, Coates, Alan S., Goldhirsch, Aron, Price, Karen N., Gelber, Richard D., Regan, Merideth M., Fleming, Gini F., Francis, Prudence A., Burstein, Harold J., Ciruelos, Eva, Bellet, Meritxell, Pavesi, Lorenzo, Lluch, Ana, Visini, Marilena

Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V

- Colleoni, Marco, Sun, Zhuoxin, Goldhirsch, Aron, Price, Karen N., Karlsson, Per, Forbes, John F., Thürlimann, Beat, Gianni, Lorenzo, Castiglione, Monica, Gelber, Richard D., Coates, Alan S.

Impact of CYO19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

- Johansson, Harriet, Gray, Kathryn P., Colleoni, Marco, Rabaglio, Manuela, Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Kammler, Roswitha, Bonanni, Bernardo, Walley, Barbara A., TEXT principal investigators,, Pagani, Olivia, Chirgwin, Jaqueline, Francis, Prudence, Regan, Meredith M., Viale, Giuseppe, Aristarco, Valentina, Macis, Debora, Puccio, Antonella, Roux, Susanne, Maibach, Rudolf